About Anima Biotech
Anima Biotech is pioneering Translation Control Therapeutics, a new class of drugs that control protein translation. Our novel platform enables for the first time to visualize and specifically control the synthesis of target proteins. By targeting the mechanisms that specifically regulate the process of mRNA translation, we discover small molecules that either decrease or increase a target protein’s production, enabling a new strategy and new hope against hard and undruggable targets.
Our novel science is backed by 5 granted patents, 14 peer-reviewed publications and a network of 17 scientific collaborations.
We are strategically structured to partner with Pharma in multiple therapeutic areas. In July 2018 we signed a collaboration agreement with Lilly for the use of our technology in the discovery and development of Translation Inhibitors of Several Protein Targets.
At the same time, we are moving our own fast pipeline growing forward. Our current programs are in Fibrosis (inhibiting the synthesis of Collagen type I), Viral infections (Respiratory Syncytial Virus – interfering with viral protein synthesis), Oncology (C-Myc translation inhibitors) and Huntington's disease (monitoring mutant Huntingtin translation pausing).